Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Rhea-AI Summary

Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in Maxim Group's 2024 Healthcare Virtual Summit. The company's CEO, Alexandra MacLean, M.D., will engage in a fireside chat on Tuesday, October 15, 2024, at 1:30 PM ET.

The event will be accessible to registered attendees, and investors can sign up or log in to the conference through a provided link. This participation highlights Avenue Therapeutics' commitment to engaging with the investment community and sharing insights about their developments in the neurologic disease treatment sector.

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.

The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here.

About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA_A α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.

Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com

FAQ

When is Avenue Therapeutics (ATXI) participating in Maxim Group's 2024 Healthcare Virtual Summit?

Avenue Therapeutics (ATXI) is participating in Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024, with a fireside chat scheduled for 1:30 PM ET.

Who will represent Avenue Therapeutics (ATXI) at the Maxim Group's 2024 Healthcare Virtual Summit?

Alexandra MacLean, M.D., the Chief Executive Officer of Avenue Therapeutics, will represent the company at the Maxim Group's 2024 Healthcare Virtual Summit.

What is the focus of Avenue Therapeutics (ATXI) as a specialty pharmaceutical company?

Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases.

How can investors attend Avenue Therapeutics' (ATXI) fireside chat at the Maxim Group's 2024 Healthcare Virtual Summit?

Investors can sign up or log in to attend Avenue Therapeutics' (ATXI) fireside chat at the Maxim Group's 2024 Healthcare Virtual Summit through a registration link provided by the company.